2026 Employer Playbook for Midyear PBM Performance Audits: Ensuring Contract Compliance, Rebate Integrity, and Real-Time Claim Accuracy
When a “set it and forget it” pharmacy contract backfires
Many employers assume that once a pharmacy benefit contract is in place, the savings will simply follow. But by midyear, CFOs often discover that real drug costs aren’t lining up with projections. The issue usually isn’t higher utilization. It’s contract leakage, the ongoing gap between what the PBM promised and what the plan actually receives in pricing, rebates, or guarantees.
As of 2026, three PBMs run most of the market. In 2025, 80% of all equivalent prescription claims were processed by three companies: CVS Caremark (CVS Health), Express Scripts (Cigna), and Optum Rx (UnitedHealth Group), according to Drug Channels Institute’s March 2026 review. Their size and vertical integration make it tough for employers to confirm contract performance without deliberate midyear checks. Skip that step, and procurement teams lose visibility into whether pricing, accuracy, and rebate guarantees are being met.
Auditing for contract compliance in the Net Pricing Drug Channel era
Drug Channels’ 2026 analysis of the “Net Pricing Drug Channel” described a move away from rebate-heavy models toward clearer value chains. For employers, that shift makes midyear audits more about confirming alignment than looking backward. A contract written in 2024 may no longer match how a PBM calculates net rates under 2026 structures. That misalignment can quietly reshape plan performance.
Verification starts by matching invoices to contract terms on pricing and network rates. Employers should check that the PBM’s definitions of brand, specialty, and generic drugs align with the categories driving financial guarantees. Even small variances alter year-end results by several points of trend. Some independent PBMs still rely on larger firms for processing or rebate work, and their category rules can differ, so clarity is essential. Details matter here.
Rebate integrity: tracing every penny back to the plan
More audits now center on rebate flow, the biggest swing factor in plan savings. Under the 2026 Net Pricing environment, rebate-heavy PBM strategies face scrutiny. Transparency demands are forcing each participant to show how value moves through contracts. So rebate verification can’t wait until year-end; it needs to happen midyear.
An effective audit compares the dispensed drug mix against the rebate expectations spelled out in the contract. It examines whether the PBM has withheld any fees or manufacturer incentives that belong to the plan. Timing also matters. When pass-throughs lag by quarters, employers experience artificial cost surges that skew renewals and stop-loss projections. Auditors skilled in rebate analysis can catch these timing gaps early and help recover funds before fiscal close.
Rebate reviews often expose formulary alignment problems too. When data show member use drifting toward brands outside preferred tiers, that’s a signal to recalibrate communication or prior authorization rules. Adjusted midyear, those changes can bring utilization back in line with rebate-eligible drugs and lift overall plan value.
Real-time claim accuracy and systems auditing
Auditing isn’t just spreadsheet work anymore. Real-time claim feeds now let employers test pricing accuracy as transactions happen. Because many smaller PBMs run on large vendors’ systems, errors can cascade before detection. Midyear audits should include transaction-level checks to confirm that discounts, dispensing fees, and cost sharing mirror what the benefit design requires.
This scrutiny is critical in a vertically integrated market. Drug Channels’ 2026 PBM Industry Update noted that large PBMs double as wholesalers, specialty pharmacies, and insurers. Those overlapping roles can influence internal transfer pricing and, ultimately, employer cost. Real-time accuracy audits help flag spreads that persist even under “pass-through” deals. Testing just a quarterly sample of top drugs often reveals discrepancies soon enough to correct them before renewal.
Practical steps to run a midyear audit without overwhelming your team
Employers don’t need to take this on alone. Third-party auditors or benefit consultants can organize reviews around three outputs: a contract compliance summary, a rebate integrity comparison, and a claim-level accuracy test for a defined subset. Many schedule this work in late Q2, leaving time to address findings before fiscal reporting. Standard contracts already require PBMs to supply extracts sufficient for that analysis.
These audits also strengthen employers’ hand at renewal. Going into Q4 with verified data on claim accuracy, pricing, and rebate yield shifts the discussion from PBM-provided summaries to hard metrics. It reduces volatility and clarifies where contract terms need updates. Some employers treat it as part of their ERISA fiduciary oversight, routine verification of how financial flows are handled.
Why 2026 audits matter more than ever
Drug Channels Institute noted that the “Big Three PBMs’ dominance persists, but they face growing regulatory and competitive constraints.” Those pressures are changing how rebates and fees are reported. Older contracts may not capture current transparency rules. Midyear audits let plan sponsors adapt in real time instead of waiting for renewal, preparing them for expanding rebate disclosure and net-price models expected through 2027.
Employers often describe these audits as a shift in mindset. Once verification becomes habit, teams forecast spending more confidently and see PBM performance more clearly. It stops being reactive work and becomes partnership. The 2026 environment, tight oversight, tighter integration, rewards that diligence.
For employer-side PBM benchmarking and contract model comparisons, see RxPBM.ai. For pricing verification references and ingredient-level data sources, visit RxInfo.ai.
Sources
Drug Channels: PBM Shakeout: How Vertical Integration Is Reshaping What’s Next (2026)